Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419371 | 0.79 | HRH2 (0.47) | MEN1KMT2ATP53NPC1KDM4E | |
| SCHEMBL28753638 | 0.79 | ADORA1 (0.59) | KDRSYKABCG2EGFR | |
| SCHEMBL27612697 | 0.78 | RHOA (0.58) | SYKMEN1KMT2ANPC1RAB9A | |
| SCHEMBL28757179 | 0.76 | ABL1 (0.52) | SYKTP53NPC1KDM4ETSHR | |
| SCHEMBL7564951 | 0.74 | KDR (0.58) | KDRSYKADRB2ABCG2ABCB1 | |
| SCHEMBL2779096 | 0.74 | BRAF (0.52) | KDRADRB2NPC1RAB9AABCG2 | |
| SCHEMBL1039755 | 0.71 | MEN1 (0.50) | KDRSYKMEN1KMT2ATP53 | |
| SCHEMBL16146408 | 0.68 | BRAF (0.51) | KDRADRB2CDK1CDK2EGFR | |
| SCHEMBL30490523 | 0.68 | NFKB1 (0.53) | KDRCDK1MEN1KMT2ANPC1 | |
| SCHEMBL16146409 | 0.68 | BRAF (0.66) | CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786783-A1 | SYNTHESIS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060058525-A1 | Synthesis of 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2006028833-A1 | SYNTHESIS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058525-A1 | Synthesis of 2,4-pyrimidinediamine compounds | TYMS, DPYD, TYMP | KDR 1306/4885SYK 2486/4885ADRB2 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.